CTCBio Q1 Operating Profit Surges; Consolidated Net Income Turns to 3.5B Won Surplus
Revenue of KRW 34.4 billion (slight increase from KRW 34.1 billion YoY), operating profit of KRW 4.6 billion (sharp increase from KRW 0.9 billion YoY), consolidated net income turned to surplus of KRW 3.5 billion (vs. net loss of KRW 0.6 billion YoY)
Separate revenue KRW 31.8 billion, operating profit KRW 4.6 billion, net income KRW 3.4 billion (significant increase from KRW 26.7 billion, KRW 1.0 billion, KRW 0.07 billion respectively YoY)
Debt ratio improved to 92.4% from 97.0% at year-end 2025, net debt ratio improved to 27.5% from 30.6%
Cash and cash equivalents of KRW 18.2 billion, total borrowings of KRW 35.7 billion (short-term KRW 26.5 billion, long-term KRW 9.2 billion)
Pending lawsuits: 10 cases (3 as plaintiff, 7 as defendant), total claim amount approx. KRW 11.8 billion (company as defendant KRW 8.5 billion)
Credit rating BB+ (Korea Data Rating), accumulated deficit of KRW 48.8 billion (consolidated)
No dividends paid, no share buyback/cancellation plans
Subsidiary CTCBio Co., Ltd. in capital impairment state